Rimonabant Acomplia

When it comes to most common nutritional disorders in the western world, obesity tops the chart with the lofting figure. Better classified as a body mass index above 30, the common ailment crops up with an excessive accumulation of fat from fat contained food stuffs. And in the U.S and Europe, its frequency has gone up to an extreme high and thus is counted among epidemics.

As per the data released by the World Health Organization, in some European expanses, more than 70% of men between the age-group of 55 to 64 years are medically obese or overweight and nearly 70% women of the same age-group are also victim of obesity. More significantly, one out of five Americans is obese and one out of three is overweight.

In addition, it is likely that the mounting rate of childhood obesity will further lend an edge to obesity in the middle-age group in the near future. And not only this, the disheartening disease also gives birth to cardiovascular problems, type 2 diabetes, breast and colorectal cancer. Furthermore, the increase in weight also results major alterations in the levels of cholesterol and blood lipid. This is where the Sanofi-Aventis’s acomplia comes to rescue and makes a difference among all available. Acomplia, also distinguished as Rimonabant, works on the notion that if cannabinoid (CB1) receptors play a major role in controlling the food consumption, appetite might be effectively controlled and reduced by putting up a grasp on the action of cannabinoid (CB1) receptors.

Acomplia diet pills basically are selective CB1 endocannabiniod receptor antagonist that is meticulously primed for the treatment of obesity. In the clinical development, acomplia is the most sophisticated endocannabiniod receptor antagonist which tenders a new therapeutic approach to control appetite and weight gain. In addition, these weight loss pills also have an unequaled potential to treat and control smoking binge as it is believed that the endocannabiniod system also exercise a strong control over body’s reaction to tobacco urge.

“Perth researchers will test a new anti-obesity pill on West Australians in the hope it will not only help them lose weight but reduce their risk of heart disease by boosting levels of HDL, or “good” cholesterol.

The Royal Perth Hospital study, part of an international trial, could prove the weight-loss pill rimonabant, sold as Acomplia, can help ward off the condition known as metabolic syndrome, a particularly highrisk form of obesity which entails problems controlling blood pressure, cholesterol and insulin.

RPH professor of medicine Gerald Watts, who specialises in metabolic disorders, said the drug was expected to be approved for Australia within a few months and the hospital aimed to recruit 15 to 20 patients as part of the 80 being studied worldwide.

“We’re interested in the mechanism of how this drug works and the role it could play in obese people who have several risk factors for heart disease, one of which is low HDL cholesterol, or metabolic syndrome,” he said. ”

“Sanofi-Aventis says that it intends to challenge in the courts the decision made by the German Ministry of Health which states that the firm’s anti-obesity drug Acomplia will not be reimbursed.

The Ministry of Health has upheld a recommendation from the German Federal Joint Committee, the G-BA, which said in October that it believes funding treatment with Acomplia (rimonabant) is inappropriate because it is a ‘lifestyle’ drug, a viewpoint which Sanofi disagrees with vigorously.

The French drugmaker has argued that Acomplia should be covered because it helps lower the risk of developing diabetes and cardiovascular disease, in addition to aiding weight loss. Indeed, Sanofi recently presented data from a Phase III trial of Acomplia which shows that treatment-naive patients with type 2 diabetes who received the drug experienced significant improvements in blood glucose control and weight loss, compared to those who took placebo.”